Drug Trial Radar · NCT06101329
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
253
Actual
Start
Nov 17, 2023
Primary completion
Jul 22, 2026
Study completion Jan 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- HIV Prevention Trials Network
- First posted
- Oct 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the general acceptability of LEN injections and oral F/TDF in US cisgender women.
Conditions
- Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir TabletDrug
Tablets administered orally without regard of food
Lenacapavir InjectionDrug
Injection administered subcutaneously
Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)Drug
200/300mg fixed dose combination (FDC) tablets administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN) at the End of Week 26Time frame: Week 26
- PK Parameter: Ctrough for LEN at the End of Week 52Time frame: Week 52
- Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: First dose date up to 30 days post last dose at Week 78
- Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory AbnormalitiesTime frame: First dose date up to 30 days post last dose at Week 78
- General Acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Acceptability Questionnaire ResponsesTime frame: Up to Week 52
- Satisfaction With Use of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Satisfaction Questionnaire ResponsesTime frame: Up to Week 52
- Willingness to Use LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Willingness to Use Questionnaire ResponsesTime frame: Up to Week 52
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
UAB, 1917 Research Clinic
Birmingham, Alabama
UCSD Antiviral Research Center (AVRC)
San Diego, California
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
Ponce de Leon Center Clinical Research Site
Atlanta, Georgia
Fenway Health
Boston, Massachusetts
Rutgers New Jesey Medical School - Clinical Research Center
Newark, New Jersey
Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine
New York, New York
Harlem Prevention Center CRS
New York, New York
ICAP at Columbia University - Bronx Prevention Center
The Bronx, New York
NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Penn Prevention Research Unit
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.